ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. If necessary, this list will be updated with every issue of *PF*. This information will also be available as a cumulative table in future *Supplements* and will appear in its corrected form in a future annual edition of *USP–NF*. Errata are considered to be items erroneously published that have not received the approval of the Council of Experts and that do not reflect the official requirement. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

USP 32–NF 27 **Page**	**Title**	**Section**	**Description**
307	⟨786⟩ *Particle Size Distribution Estimation by Analytical Sieving*	*Table 1*	Column 5 heading: Change ''Recommended USP Sieves (mesh)'' to: Recommended USP Sieves (microns)
817	*Reagent Specifications*	*Decanol*	Line 1: Change ''[25339-17-7]'' to: [112-30-1]
924	*Description and Solubility*	*Polydextrose*	Line 3: Change ''insoluble in alcohol.'' to: soluble in alcohol.
1175	*Betadex*	*Reducing sugars*	Line 3 under *Standard solution*: Change ''1.0 g of anhydrous Betadex.'' to: 1 mL of 10 mg/mL Betadex solution.
1296	*Paraffin*	*Alkalinity*	Line 2: Change ''methyl red TS:'' to: methyl red TS 2:
2466	*Gadodiamide*	*Content of gadolinium*	Line 3 under *Procedure*: Change ''342 nm'' to: 342.3 nm
2963	*Metoprolol Succinate*	*Assay*	Line 6 under *Chromatographic system*: Change ''between metoprolol related compound A and metoprolol related compound B is not less than 1.5; and the resolution, *R,* between metoprolol related compound B and metoprolol related compound C is not less than 2.5.'' to: between metoprolol related compound A and metoprolol related compound B is not less than 2.5; and the resolution, *R,* between metoprolol related compound B and metoprolol related compound C is not less than 1.5.
3001	*Monensin*	*Assay*	Line 1 under *Derivatizing reagent*: Change ''3 g of vanillin in a mixture of methanol and sulfuric acid (95:2).'' to: 3 g of vanillin in a mixture of 95 mL of methanol and 2 mL of sulfuric acid.

USP 32–NF 27			
Page	**Title**	**Section**	**Description**
3113	*Norgestimate*	*Chromatographic purity*	Line 2 under *Test 1*: Change ''*Diluent, Mobile phase, Sensitivity solution,* and *Chromatographic system*—'' to: *Diluent, Mobile phase,* and *Sensitivity solution*— Line 4 under *Chromatographic system*: Change ''1.2 mL per minute. Chromatograph the *Resolution solution,*'' to: 1.2 mL per minute. The column temperature is maintained at about 40°. Chromatograph the *Resolution solution,* Line 8 under *Chromatographic system*: Change ''related compound A, and 1.0 for (*E*)-norgestimate;'' to: related compound A, 0.86 for (*Z*)-norgestimate, and 1.0 for (*E*)-norgestimate; Line 11 under *Chromatographic system*: Change ''is not less than 1.5.'' to: is not less than 1.5; the tailing factor for (*E*)-norgestimate and for (*Z*)-norgestimate is not more than 1.5; and the relative standard deviation for replicate injections, determined from the peak area ratio of (*E*)-norgestimate to (*Z*)-norgestimate, is not more than 2.0%. Chromatograph the *Sensitivity solution*, and record the peak areas as directed for *Procedure*: the signal-to-noise ratio for (*Z*)-norgestimate is not less than 3.0.
3220	*Penicillamine*	*Limit of penicillin activity*	Line 1 under *Standard preparation*: Change ''*Table 2* under *Antibiotics—Microbial Assays* ⟨81⟩'' to: *Table 1* under *Antibiotics—Microbial Assays* ⟨81⟩
First Supplement to USP 32–NF 27			
4066	*Isotretinoin Capsules*	*Chromatographic purity*	Line 4 under *Chromatographic system*: Change ''Chromatograph the *System suitability solution*,'' to: Chromatograph the *System suitability solution* [NOTE—The injection volume is about 20 µL.],
Online	*Estradiol Vaginal Inserts*	*Loss on Drying*	Delete the test for *Loss on drying*, which was incorrectly published in the online version of the *First Supplement to USP 32–NF 27*, and carried forward to the *Second Supplement to USP 32–NF 27*.